Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

(2011) David H. Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Osteonecrosis of the jaw and bevacizumab therapy

(2010) Catherine Van Poznak   BREAST CANCER RESEARCH AND TREATMENT

Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer

(2010) Valentina Guarneri et al.   BREAST CANCER RESEARCH AND TREATMENT

Bisphosphonate osteonecrosis of the jaw—a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention

(2010) Vinod Patel et al.   BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

(2010) Alison T. Stopeck et al.   JOURNAL OF CLINICAL ONCOLOGY

A systematic review of bisphosphonate osteonecrosis (BON) in cancer

(2010) Cesar Augusto Migliorati et al.   SUPPORTIVE CARE IN CANCER

Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents

(2009) Jeanny B. Aragon-Ching et al.   CANCER INVESTIGATION

Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid

(2008) M. A. Dimopoulos et al.   ANNALS OF ONCOLOGY

Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan

(2008) C. I. Ripamonti et al.   ANNALS OF ONCOLOGY

Osteonecrosis of the Jaw in Patients Receiving Intravenous or Oral Bisphosphonates

(2008) Amber E King et al.   PHARMACOTHERAPY